Voyager Therapeutics (VYGR) and Its Competitors Critical Survey
Voyager Therapeutics (NASDAQ: VYGR) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Voyager Therapeutics to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
This is a summary of current ratings and recommmendations for Voyager Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Voyager Therapeutics Competitors||480||2262||6183||119||2.66|
Voyager Therapeutics presently has a consensus target price of $27.86, suggesting a potential upside of 28.91%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.46%. Given Voyager Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than its competitors.
This table compares Voyager Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Voyager Therapeutics Competitors||-3,554.56%||-117.73%||-43.15%|
Insider and Institutional Ownership
40.7% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.0% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Voyager Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Voyager Therapeutics||$8.31 million||-$59.32 million||-9.40|
|Voyager Therapeutics Competitors||$207.79 million||-$2.30 million||0.43|
Voyager Therapeutics’ competitors have higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Voyager Therapeutics has a beta of 4.49, indicating that its stock price is 349% more volatile than the S&P 500. Comparatively, Voyager Therapeutics’ competitors have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Voyager Therapeutics beats its competitors on 7 of the 12 factors compared.
About Voyager Therapeutics
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.